WallStreetZenWallStreetZen

NASDAQ: CYCC
Cyclacel Pharmaceuticals Inc Stock Ownership - Who owns Cyclacel Pharmaceuticals?

Insider buying vs selling

Have Cyclacel Pharmaceuticals Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Paul McBarronE. VP Fin CFO COO and Secretary2023-12-211,886$3.32
$6.25kBuy
Spiro George RombotisPresident and CEO2023-12-216,070$3.32
$20.12kBuy

1 of 1

CYCC insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CYCC insiders and whales buy or sell their stock.

CYCC Shareholders

What type of owners hold Cyclacel Pharmaceuticals Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Austin W. Greenhouse David M. Marxe333.02%2,806,900$8.14MInsider
Stanley Morgan270.14%2,276,852$6.60MInsider
James E. Flynn164.33%1,385,091$4.02MInsider
Kevin C. Tang50.51%425,700$1.23MInsider
Spiro George Rombotis8.15%68,658$199.11kInsider
Eastern Capital Ltd7.81%65,863$191.00kInsider
Judy Chiao6.88%58,008$168.22kInsider
Lloyd Sems6.11%51,529$149.43kInsider
Kenneth M. Ferguson5.33%44,952$130.36kInsider
Karin L. Walker4.82%40,602$117.75kInsider

1 of 3

CYCC vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CYCC1.23%98.77%Net BuyingNet Buying
INM13.28%11.17%Net BuyingNet Buying
PHIO0.49%99.51%Net BuyingNet Selling
QLGN0.87%99.13%
SLRX2.20%97.80%

Cyclacel Pharmaceuticals Stock Ownership FAQ

Who owns Cyclacel Pharmaceuticals?

Cyclacel Pharmaceuticals (NASDAQ: CYCC) is owned by 11.14% institutional shareholders, 893.19% Cyclacel Pharmaceuticals insiders, and 0.00% retail investors. Austin W. Greenhouse David M. Marxe is the largest individual Cyclacel Pharmaceuticals shareholder, owning 2.81M shares representing 333.02% of the company. Austin W. Greenhouse David M. Marxe's Cyclacel Pharmaceuticals shares are currently valued at $8.14M.

If you're new to stock investing, here's how to buy Cyclacel Pharmaceuticals stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.